The Tempo Team
Profile
Westbrook Weaver, PhD
Founder, Director, & CEO
Westbrook is a co-inventor of Tempo’s MAP material, and is the driving force behind early development at the company. He leads strategic and business development, as well as defining the critical path and leading company fundraising.
Profile
Donald Griffin, PhD
Founder, Director, & CSO
Don is a co-inventor of the MAP technology, and a leading expert in biomaterial tissue engineering. He has over 8 years of experience as a researcher and Bioengineering professor, and leads scientific & new technology efforts at Tempo.
Profile
Stephanie Deshayes, PhD
Principal Scientist
Stephanie is an expert in organic chemistry, biomaterials, and drug delivery systems, with over 12 years of experience in the field. She leads Tempo’s on-the-ground efforts in developing the MAP platform and new technology breadth.
Profile
Sam Timko
Director of Product Development
Sam is a biotechnology and life science industry professional, with 10 years of experience in biologics manufacturing and FDA regulatory development. He leads Tempo’s manufacturing process and product/regulatory development pillar.
Profile
Jumana Alhamdi, PhD
Project Scientist
Jumana has over 5 years of experience in orthopedic tissue engineering and immunology. She brings unique expertise to new technology development of Tempo’s biomaterial technology for multiple tissue applications.
Tempo Advisors
Profile
Philip Scumpia, MD PhD
Founder, Clinical Advisor
Dr. Scumpia, a co-inventor of Tempo’s MAP technology, is a diplomate of the American Board of Dermatology and a member of the American Society of Dermatopathology and Society of Investigative Dermatology, and a Ph.D. immunologist. He currently practices clinical dermatology and dermatopathology at both UCLA health System and the West Los Angeles Veterans Affairs, and runs an NIH-funded research program as a clinical professor in the David Geffen School of Medicine at UCLA. Dr. Scumpia has received of numerous grants from the American Skin Cancer Association, the Dermatology Foundation, and the NIH. He has published 50 peer-reviewed manuscripts, including manuscripts in the prestigious journals Nature Materials and Nature Cell Biology.
Profile
Tatiana Segura, PhD
Founder, Scientific Advisor
Dr. Segura is a professor of Biomedical Engineering, Neurology and Dermatology at Duke University and is a co-inventor of Tempo’s MAP Technology. Professor Segura's Laboratory studies the use of materials for minimally invasive in situ tissue repair. On this topic, she has published over 60 peered reviewed publications. She has been recognized with the Outstanding Young Investigator Award from the American Society of Gene and Cell Therapy, the American Heart Association National Scientist Development Grant, and the CAREER award from National Science Foundation. She was Elected to the College of Fellows at the American Institute for Medical and Biological Engineers (AIMBE) in 2017.
Board of Directors
Profile
Richard Hancock
Rick has over 35 years of experience in biotechnology management where he has built global marketing and sales campaigns, structured and executed large contracts, licensing, partnerships, brought in significant venture investment, and taken companies through acquisition. Rick is crucial for Tempo’s business development strategy and corporate operations.
Profile
Dino Di Carlo, PhD
Dino is a co-founder and co-inventor of Tempo's technology. He is the vice-chair of Bioengineering at UCLA, with 100+ peer reviewed journal articles and 20+ patents. He is also an experienced biotechnology entrepreneur, with two venture-backed companies. Dino plays a critical role in Tempo's early development.
Profile
Steven Richieri
Steve has over 30 years of experience in the biotechnology and medical device arena. He has founded 4 successful companies where he served various executive roles including CEO and COO. He has regulatory experience, with 22 approved FDA submissions including 510(k), De Novo, and PMA mechanisms. Steve helps direct Tempo’s business development and regulatory execution.